Loading...
New‐generation anticancer drugs and medication‐related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy
Association of immunotherapy and/or chemotherapy and/or targeted therapy, in sequence or as single therapies, may induce osteonecrosis of the jaw. Multidisciplinary team management of these patients should be provided.
Na minha lista:
| Udgivet i: | Clin Case Rep |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7813008/ https://ncbi.nlm.nih.gov/pubmed/33489133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3418 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|